About AEON BioPharma
AEON BioPharma is a publicly listed company based in Newport Beach (United States) founded in 2018. Bio-therapeutics for nervous system conditions are developed and provided. AEON BioPharma has raised $30 million across 2 funding rounds from investors including Daewoong Pharmaceutical. The company has 5 employees. Its chief executive, as recorded, is Marc Forth. AEON BioPharma offers products and services including ABP-450. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is AEON Biopharma, Inc. Its competitors include Biogen, Neurocrine and PTC Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
AEON BioPharma was founded in 2018 and is headquartered in Newport Beach, United States. Bio-therapeutics targeted at nervous system-related conditions are developed by the company within the biopharmaceutical sector. Operations focus on innovative treatments, including the flagship product ABP-450, a 900 kDa prabotulinumtoxinA formulation. This product is utilized for managing disabling disorders in patients, with ongoing efforts centered on clinical advancement and therapeutic delivery.
- Headquarters Newport Beach, United States
- Employees 5
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website aeonbiopharma.com
- Social LinkedIn
- Legal Name Aeon Biopharma, Inc.
- Net Profit-$39.22 M (USD)-193.37as on Dec 31, 2025
- EBITDA-$16.82 M (USD)39.32as on Dec 31, 2025
- Total Equity Funding$30M (USD)
in 2 rounds
- Latest Funding Round$54.5M (USD), Post-IPO
Aug 2022
- Investors
- Employee Count5
Products & Services of AEON BioPharma
AEON BioPharma offers a comprehensive portfolio of products and services, including ABP-450.
Neurotoxin treatment for nerve and muscle-based disorders
Funding Insights of AEON BioPharma
AEON BioPharma has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $54.5 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 2
- Last Round Post-IPO — $54.5M
- First Round $30M
(Sep 2020)
- Investors Count 1
All 2 funding rounds of AEON BioPharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $54.5M | Post-IPO | – | – | – |
| Sep 2020 | $30M | Series B | – | Daewoong Pharmaceutical | – |
1 investors in total: 1 institutional.
Investors in AEON BioPharma
AEON BioPharma has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Daewoong Pharmaceutical.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for gastrointestinal disorders and related diseases are developed. | 1945 | daewoong.com | Seoul, South Korea |
Investor details for AEON BioPharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AEON BioPharma
7 people are tracked at AEON BioPharma (3 in leadership, 4 in board & advisors); the tracked headcount is 5.
| Name | Role | Group |
|---|---|---|
Marc Forth | CEO & President | Leadership |
Alex Wilson | EVP, Chief Legal Officer & Secretary | Leadership |
Chad Oh | Chief Medical Officer | Leadership |
Eric Carter | Board Member | Board & advisors |
Shelley Thunen | Board Member | Board & advisors |
Jost Fischer | Chairman & Board Member | Board & advisors |
Robert Palmisano | Board Member | Board & advisors |
Complete people profiles for AEON BioPharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AEON BioPharma
AEON BioPharma is a publicly listed company on the AMEX with ticker symbol AEON in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Apr 2021
- Listed onNYSEAMERICAN: AEON
- Listed entityAEON Biopharma, Inc.
- Exchange sectorHealth technology
- ISINUS00791X2099
- Share price$0.23 (-6.47% on the day) · 2026-10-13
- Market capitalisation$11.5M
- Price to earnings0.2
- EPS (diluted, trailing year)$-3.77
- Volume (last session)1,291,335
Financials of AEON BioPharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$39.2M | -$16.8M | |
| 2024 | $42.0M | -$27.7M | |
| 2023 | -$384.6M | -$52.7M | |
| 2022 | -$52.6M | -$48.4M | |
| 2021 | $8.2M | -$1.9M |
Detailed financial statements for AEON BioPharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of AEON BioPharma
4 dated milestones of AEON BioPharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AEON BioPharma is founded.
- Funding First funding round of $30.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $54.5M.
Competitors of AEON BioPharma
AEON BioPharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, Neurocrine and PTC Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders | |
| ptcbio.com | 1998 | South Plainfield, United States | $248.1M | 995 | Small molecule drugs for rare diseases are developed. |
Detailed competitors of AEON BioPharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AEON BioPharma
The website of AEON BioPharma (aeonbiopharma.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 39.3% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as AEON BioPharma (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aeon Biopharma
Complete news archive for AEON BioPharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AEON BioPharma
AEON BioPharma was founded in 2018 and raised its 1st funding round 2 years after it was founded.
AEON BioPharma is headquartered in Newport Beach, United States. It is registered at Newport Beach, California, United States.
Marc Forth is the CEO of AEON BioPharma, as recorded in our data.
AEON BioPharma is a funded company, having raised a total of $30M across 2 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Sep 2020.
AEON BioPharma has 5 employees.
AEON BioPharma was founded in 2018 and is headquartered in Newport Beach, United States. Bio-therapeutics targeted at nervous system-related conditions are developed by the company within the biopharmaceutical sector. Operations focus on innovative treatments, including the flagship product ABP-450, a 900 kDa prabotulinumtoxinA formulation. This product is utilized for managing disabling disorders in patients, with ongoing efforts centered on clinical advancement and therapeutic delivery.
AEON BioPharma's top competitors include PTC Therapeutics, Neurocrine and Biogen.
AEON BioPharma offers ABP-450.
Yes, AEON BioPharma is publicly traded on AMEX under the ticker symbol AEON.
AEON BioPharma has 1 investor. Key investors include Daewoong Pharmaceutical.
AEON BioPharma operates through Aeon Biopharma, Inc..